Jupiter Wellness Submitted a Pre-IND Meeting Request with the US FDA for its Proposed Clinical Program of JW-100 as a Treatment for Mild to Moderate Eczema

Following receipt of a Pre-Assignment number from the FDA Jupiter Wellness requests Pre-IND meeting JUPITER, FL / August 23, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a developer of enhanced skin care therapeutics and treatments focused on the endocannabinoid system today announced it has submitted a pre-IND (Investigational New Drug) meeting request with the U.S. Food […]

Jupiter Wellness Applies for IND number from the US Food and Drug Administration

Following positive results from the JW-100 investigator initiated trials for Eczema, Jupiter Wellness to commence US FDA program JUPITER, FL / August 16, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced it has requested an IND number from the US Federal Drug Administration in preparation for a pre-IND submission to review preclinical and clinical studies […]